alpha-aminopyridine has been researched along with Myelodysplastic Syndromes in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Carayannopoulos, L; Cheng, Y; Li, Y; Reyes, J; Tong, Z; Wang, X; Zhou, S | 1 |
| Santini, V | 1 |
| Attar, EC; Collins, R; de Botton, S; DiNardo, CD; Fathi, AT; Frattini, MG; Kantarjian, HM; MacBeth, KJ; Pollyea, DA; Roboz, GJ; See, WL; Sekeres, MA; Stein, EM; Stone, RM; Tallman, MS; Tosolini, A; Xu, Q | 1 |
| Arber, DA; Erba, HP | 1 |
| Kiyoi, H | 1 |
| Ding, K; Fu, R; Li, L; Liu, C; Liu, H; Liu, Z; Wang, Y | 1 |
2 review(s) available for alpha-aminopyridine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
Topics: Aged; Aminopyridines; Antineoplastic Agents; Blood Cells; Bone Marrow; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; PubMed; Triazines | 2020 |
Overview: A New Era of Cancer Genome in Myeloid Malignancies.
Topics: Aminopyridines; Anemia, Aplastic; Antineoplastic Agents; Benzimidazoles; Clonal Evolution; Genome, Human; Hematopoiesis; Histone-Lysine N-Methyltransferase; Humans; Immunosuppressive Agents; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Mutation; Myelodysplastic Syndromes; Triazines | 2015 |
1 trial(s) available for alpha-aminopyridine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Topics: Aged; Aminopyridines; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hyperbilirubinemia; Isocitrate Dehydrogenase; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Triazines | 2020 |
3 other study(ies) available for alpha-aminopyridine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Topics: Aged; Aminopyridines; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Digoxin; Drug Interactions; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Pharmaceutical Preparations; Recurrence; Rosuvastatin Calcium; Triazines | 2022 |
Enasidenib: a magic bullet for myelodysplastic syndromes?
Topics: Aminopyridines; Humans; Myelodysplastic Syndromes; Triazines | 2020 |
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Topics: Acetylation; Aminopyridines; Apoptosis; Benzamides; Cell Line; Cell Line, Tumor; Cell Proliferation; G1 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Histones; Humans; Myelodysplastic Syndromes; Resting Phase, Cell Cycle | 2016 |